BBHC
TCRX icon

Brown Brothers Harriman & Co’s TScan Therapeutics TCRX Stock Holding History

Brown Brothers Harriman & Co’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$144K Hold
143,051
– – ﹤0.01% 865
2025
Q4 		$143K Hold
143,051
– – ﹤0.01% 834
2025
Q3 		$260K Hold
143,051
– – ﹤0.01% 627
2025
Q2 		$207K Hold
143,051
– – ﹤0.01% 627
2025
Q1 		$197K Hold
143,051
– – ﹤0.01% 560
2024
Q4 		$435K Hold
143,051
– – ﹤0.01% 432
2024
Q3 		$712K Buy
143,051
+67,027
+88% +$404K ﹤0.01% 343
2024
Q2 		$445K Buy
+76,024
New +$599K ﹤0.01% 395

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Brown Brothers Harriman & Co's TCRX Position: Q1 2026 in Review

Brown Brothers Harriman & Co held its TScan Therapeutics (TCRX) position steady in Q1 2026 at 143,051 shares worth $144K. The position accounts for ﹤0.01% of the portfolio, ranked #865.

Brown Brothers Harriman & Co first reported a position in TCRX in Q2 2024 and has held it in 8 quarters since. The position peaked at $712K in Q3 2024. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

  • Brown Brothers Harriman & Co held 143,051 shares of TScan Therapeutics worth $144K as of Q1 2026.
  • Brown Brothers Harriman & Co left its TScan Therapeutics share count unchanged in Q1 2026.
  • TScan Therapeutics made up ﹤0.01% of Brown Brothers Harriman & Co's portfolio in Q1 2026, its #865 holding.
  • Brown Brothers Harriman & Co first reported a position in TScan Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Brown Brothers Harriman & Co's TScan Therapeutics position peaked at $712K in Q3 2024.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on Brown Brothers Harriman & Co's 13F filing for Q1 2026, filed 14 May 2026.